Bank of New York Mellon Corp Has $756,000 Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

Bank of New York Mellon Corp decreased its stake in BeiGene, Ltd. (NASDAQ:BGNE) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,299 shares of the company’s stock after selling 99 shares during the period. Bank of New York Mellon Corp’s holdings in BeiGene were worth $756,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in BGNE. Headlands Technologies LLC bought a new position in shares of BeiGene during the 1st quarter worth approximately $50,000. Benjamin F. Edwards & Company Inc. boosted its position in BeiGene by 51.5% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after buying an additional 279 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in BeiGene during the 4th quarter worth $183,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of BeiGene in the fourth quarter valued at approximately $215,000. Finally, Acadian Asset Management LLC raised its stake in shares of BeiGene by 204.1% during the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after acquiring an additional 849 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BGNE. JPMorgan Chase & Co. lifted their price objective on BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Bank of America dropped their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. JMP Securities assumed coverage on shares of BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective for the company. Finally, Citigroup lifted their price objective on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, BeiGene presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.21.

BeiGene Stock Performance

Shares of BGNE opened at $201.99 on Monday. The stock has a 50-day moving average price of $182.24 and a 200-day moving average price of $164.51. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The company has a market cap of $19.57 billion, a PE ratio of -26.68 and a beta of 0.61. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $215.00.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, topping the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business’s revenue was up 56.1% compared to the same quarter last year. During the same period last year, the firm posted ($3.64) earnings per share. As a group, equities analysts forecast that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Insider Transactions at BeiGene

In other BeiGene news, CFO Julia Aijun Wang sold 472 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $143.90, for a total transaction of $67,920.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $160.57, for a total value of $133,915.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Julia Aijun Wang sold 472 shares of BeiGene stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $143.90, for a total value of $67,920.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,999 shares of company stock worth $2,282,183. Insiders own 7.43% of the company’s stock.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.